Arthrex has patented a method using placental tissue streamers to treat musculoskeletal injuries. The technique involves inserting the streamers into the injured tissue for repair or support. GlobalData’s report on Arthrex gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Arthrex, Cardiothoracic surgery instruments was a key innovation area identified from patents. Arthrex's grant share as of February 2024 was 100%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of musculoskeletal tissue injury using placental tissue streamers
A recently granted patent (Publication Number: US11918453B2) discloses a method for treating musculoskeletal tissue injury or degeneration in a subject by inserting placental tissue streamers into the affected tissue. The method involves inserting at least one placental tissue streamer into the injured or degenerated tissue, with specific applications for connective tissue, cartilaginous tissue, fibrous tissue, muscle tissue, or skeletal tissue injuries or degeneration. The injured or degenerated tissue can include tendons, cartilage, ligaments, intervertebral disks, bones, rotator cuff muscles, or tendons, including tears or partial thickness tears.
Furthermore, the patent details the use of various types of placental tissue or placental tissue streamers, such as amniotic tissue, chorionic tissue, umbilical cord tissue, and their combinations, including viable tissue cells, extracellular matrix, decellularized tissue, hypothermic or cryopreserved tissue, chemically preserved tissue, normothermic preserved tissue, and dehydrated, desiccated, or lyophilized tissue. The method also includes reconstituting the placental tissue streamers with solutions containing platelet-rich plasma (PRP), bone marrow concentrate (BMC), growth factors, stem cells, adipose-derived growth factors, amniotic epithelial (AE) cells, umbilical cord-derived (UCD) cells, chorionic trophoblasts, amnion-derived mesenchymal stromal cells, chorion-derived mesenchymal stromal cells, or their combinations. This innovative approach aims to provide a regenerative treatment option for musculoskeletal injuries or degeneration by utilizing the unique properties of placental tissues and their derivatives in combination with biopreservation techniques.
To know more about GlobalData’s detailed insights on Arthrex, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
